Increasing awareness of Nasal Drug Improves Demand for Nasal Drug Delivery Systems

 

Nasal Drug Delivery Systems

The nasal medication delivery method is a non-invasive alternative to invasive administrations that allows for direct access to the systemic circulation. Intranasal medication delivery is the most frequent and recommended method for treating allergic and non-allergic rhinitis, discomfort, acute migraine therapy, and nasal congestion caused by sinusitis, the common cold, or rhinitis.

Nasal medication delivery is most commonly employed when a quick start of action is required, or to reach a place where conventional routes of administration have failed. For needle-free immunisation and systemic medication administration, nasal drug delivery is also the recommended approach. Inhalers, droppers, spray pumps, nebulizers, and atomizers can all be used to provide liquid nasal solutions.

The global nasal drug delivery systems market size is estimated to be valued at US$ 48.1 billion in 2018 and is expected to witness a CAGR of 6.3% over the forecast period (2018 – 2026). The increased adoption of self-administration techniques and increasing patient preference for nasal medication delivery as a consequence of easier administration and higher efficacy are some of the primary factors driving the growth of the Nasal Drug Delivery Systems market. One of the most popular medication delivery routes among patients and healthcare providers is intranasal drug administration. This is due in large part to the nasal route's non-invasive character and the fact that medication absorbability is higher through this route.

Market Dynamics

Patient preference for nasal medicine delivery is growing as a result of its ease of use and effectiveness.

Growing adoption of self-administration practices

Restraints

Overuse of nasal sprays might lead to complications.

Challenges

Regulatory roadblocks

One of the most significant advantages of nasal medication administration is that it avoids hepatic first-pass metabolism, resulting in increased bioavailability when compared to drugs taken orally. Parenteral administration, on the other hand, is cumbersome for long-term therapeutic therapy.

Because the nasal cavity is extremely vascular, medication absorption is enhanced, resulting in a quick beginning of action. Furthermore, the convenience of administration combined with the non-invasive approach is driving nasal drug delivery system acceptance, which is propelling the market for nasal drug delivery systems forward.

However, nasal medication delivery system constraints such as histopathological toxicity or a smaller region of absorption as compared to orally delivered drugs are impeding the market's growth.

The expansion of the Nasal Drug Delivery Systems Market is also being fuelled by an increase in product releases with nasal medication delivery. In 2017, Optinose, an ENT/Allergy specialty pharmaceutical firm, got FDA clearance for its Xhance, fluticasone propionate, for the treatment of nasal polyps in adults. Xhance is a mix of the innovative Optinose Exhalation Delivery System and an aqueous solution of microfine medication delivery for topical intranasal administration by a metered atomizing spray pump. Furthermore, the medication is available in powder and liquid forms, and its bi-directional distribution overcomes the limitations of standard nasal spray.

One of the most popular medication delivery routes among patients and healthcare providers is intranasal drug administration. This is due to the non-invasive nature of this mode of delivery, as well as the fact that medication absorbability is higher via the nasal route. Furthermore, as compared to the gastro-intestinal route, the nasal route provides a less hostile environment, allowing for improved medication absorption. Furthermore, unlike certain other routes of drug administration, nasal medication delivery does not necessitate the use of a sterile technique for introducing pharmaceuticals into the body.